CTKB · Cytek Biosciences, Inc.
$4.45
-0.11 (-2.41%)
At close · Jul 24
Market Cap
$575.98M
Shares
129.14M
Cytek Biosciences, Inc. Earnings Call Transcripts
Every quarterly earnings call for Cytek Biosciences, Inc. (CTKB) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲17.7%
$40.48M
$1.63M
'22 Q3
22-11-09
·
$
$3.72M
'22 Q4
23-02-28
▲5.8%
$37.09M
−$6.81M
'23 Q1
23-05-09
▲23.7%
$49.69M
−$4.39M
'23 Q2
23-08-08
▲18.6%
$48.00M
−$6.46M
'23 Q3
23-11-09
·
$58.23M
$5.50M
'23 Q4
24-03-01
▲21%
$44.86M
−$6.17M
'24 Q1
24-05-08
▼6.2%
$46.62M
−$10.43M
'24 Q2
24-08-06
▲7.3%
$51.50M
$941,000
'24 Q3
24-11-05
▼1.3%
$57.48M
$9.64M
'24 Q4
25-01-15
▼7.6%
$41.46M
−$11.40M
'25 Q1
25-05-08
▼2.2%
$45.60M
−$5.58M
'25 Q2
25-08-14
▲1.5%
$52.29M
−$5.48M
'25 Q3
25-11-05
▲8.1%
$62.14M
−$44.08M
'25 Q4
26-02-26
LATEST
▲6.5%
$44.13M
−$18.87M
'26 Q1
26-05-07
Earnings call
FY26 · Q2
2026-08-05
Cytek Biosciences Second Quarter 2026 Earnings Conference Call
Scheduled
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-07
Cytek Biosciences, Inc. Q1 FY2026 Earnings Call
Positive tone
Q1 revenue and growth
Geographic performance
Recurring revenue (reagents and service)
Revenue
$44.13M
▲ 6.5% YoY Gross margin
48.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-26
Cytek Biosciences, Inc. Q4 FY2025 Earnings Call
Positive tone
Quarterly and annual revenue performance
2026 financial guidance and outlook
Geographic performance and end markets
Revenue
$62.14M*
▲ 8.1% YoY Gross margin
52.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-05
Cytek Biosciences, Inc. Q3 FY2025 Earnings Call
Positive tone
Geographic revenue performance
Recurring revenue growth (service and reagents)
Capital deployment and M&A
Revenue
$52.29M
▲ 1.5% YoY Gross margin
52.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-14
Cytek Biosciences, Inc. Q2 FY2025 Earnings Call
Balanced tone
Recurring revenue (reagents and service)
Revenue performance and geographic mix
Gross margin drivers and one-time items
Revenue
$45.60M
▼ 2.2% YoY Gross margin
52.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Cytek Biosciences, Inc. Q1 FY2025 Earnings Call
Cautious tone
Service and reagent recurring revenue
APAC and rest of world growth
Tariffs and macro environment
Revenue
$41.46M
▼ 7.6% YoY Gross margin
48.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-01-15
Cytek Biosciences, Inc. Q4 FY2024 Earnings Call
Positive tone
Adjusted EBITDA and profitability leverage
Cytek Cloud and bioinformatics
China demand and stimulus
Revenue
$57.48M*
▼ 1.3% YoY Gross margin
58.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-05
Cytek Biosciences, Inc. Q3 FY2024 Earnings Call
Positive tone
Instrument placements
International growth (EMEA, APAC, China)
Bioinformatics / Cytek Cloud
Revenue
$51.50M
▲ 7.3% YoY Gross margin
56.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-06
Cytek Biosciences, Inc. Q2 FY2024 Earnings Call
Balanced tone
Product launches (ESP and spectral panel tool)
U.S. market weakness and elongated sales cycles
Installed base and replacement opportunity
Revenue
$46.62M
▼ 6.2% YoY Gross margin
54.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-08
Cytek Biosciences, Inc. Q1 FY2024 Earnings Call
Positive tone
Luminex/Amnis/Guava integration
Organic revenue growth and resumption
Wuxi manufacturing facility
Revenue
$44.86M
▲ 21% YoY Gross margin
51.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-01
Cytek Biosciences, Inc. Q4 FY2023 Earnings Call
Positive tone
Luminex/Amnis/Guava acquisition integration
Geographic footprint and regions
Revenue growth and 2023 results
Revenue
$58.23M*
Gross margin
56.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-09
Cytek Biosciences, Inc. Q3 FY2023 Earnings Call
Revenue
$48.00M
▲ 18.6% YoY Gross margin
56.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
Cytek Biosciences, Inc. Q2 FY2023 Earnings Call
Revenue
$49.69M
▲ 23.7% YoY Gross margin
56.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-09
Cytek Biosciences, Inc. Q1 FY2023 Earnings Call
Revenue
$37.09M
▲ 5.8% YoY Gross margin
56.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-28
Cytek Biosciences, Inc. Q4 FY2022 Earnings Call
Revenue
$*
Gross margin
-26.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-09
Cytek Biosciences, Inc. Q3 FY2022 Earnings Call
Revenue
$40.48M
▲ 17.7% YoY Diluted EPS
$-0.01
Gross margin
66.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-10
Cytek Biosciences, Inc. Q2 FY2022 Earnings Call
Revenue
$40.16M
▲ 32.1% YoY Diluted EPS
$0.00
Gross margin
61.2%
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-11
Cytek Biosciences, Inc. Q1 FY2022 Earnings Call
Revenue
$35.06M
▲ 44.5% YoY Diluted EPS
$0.02
Gross margin
57.5%
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-23
Cytek Biosciences, Inc. Q4 FY2021 Earnings Call
Revenue
$*
Gross margin
-27.2%
Rev · 5q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-08
Cytek Biosciences, Inc. Q3 FY2021 Earnings Call
Revenue
$34.38M
▲ 37% YoY Diluted EPS
$0.00
▼ 100% YoY Gross margin
61.9%
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Showing 1–20 of 20 earnings calls
Key facts
CIK
1831915
CUSIP
23285D109
13F (30d)
20 filings
20 filers
Visit website
Investor relations